

How do physicians cope with controversial topics in existing guidelines for the management of infective endocarditis? Results of an international survey
Peer-reviewed author version

BERAUD, Guillaume; Pulcini, C.; Paño-Pardo, J. R.; Hoen, B.; Beovic, B. & Nathwani, D. (2016) How do physicians cope with controversial topics in existing guidelines for the management of infective endocarditis? Results of an international survey. In: CLINICAL MICROBIOLOGY AND INFECTION, 22 (2), p. 163-170.


DOI: 10.1016/j.cmi.2015.10.013

Handle: <http://hdl.handle.net/1942/21798>

Accepted Manuscript

How do physicians cope with controversial topics in existing guidelines for the management of infective endocarditis? Results of an international survey

Dr Guillaume Béraud, Céline Pulcini, José Ramón Paño-Pardo, Bruno Hoen, Bojana Beovic, Dilip Nathwani



PII: S1198-743X(15)00912-X

DOI: [10.1016/j.cmi.2015.10.013](https://doi.org/10.1016/j.cmi.2015.10.013)

Reference: CMI 413

To appear in: *Clinical Microbiology and Infection*

Received Date: 7 August 2015

Revised Date: 3 October 2015

Accepted Date: 9 October 2015

Please cite this article as: Béraud G, Pulcini C, Paño-Pardo JR, Hoen B, Beovic B, Nathwani D, on behalf of ESGAP, How do physicians cope with controversial topics in existing guidelines for the management of infective endocarditis? Results of an international survey, *Clinical Microbiology and Infection* (2015), doi: 10.1016/j.cmi.2015.10.013.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **Category:** Original article

2 **Title:** How do physicians cope with controversial topics in existing guidelines for the management of
3 infective endocarditis? Results of an international survey

4 **Authors:** Guillaume Béraud^{1,2,3}, Céline Pulcini^{4,5}, José Ramón Paño-Pardo⁶, Bruno Hoen^{7,8}, Bojana
5 Beovic⁹, Dilip Nathwani¹⁰, on behalf of ESGAP

6 **Authors' affiliation:**

7 1: Médecine Interne et Maladies Infectieuses, Centre Hospitalier de Poitiers, Poitiers, France.

8 2: EA2694, Université Droit et Santé Lille 2, Lille, France.

9 3: Interuniversity Institute for Biostatistics and statistical Bioinformatics, Hasselt University, Hasselt,
10 Belgium.

11 4: Service de Maladies Infectieuses, CHU Nancy, France

12 5: EA 4360 Apemac, Université de Lorraine, Université Paris Descartes, Nancy, France.

13 6: Unidad de Enfermedades Infecciosas y Microbiología Clínica, Departamento de Medicina Interna,
14 Hospital Universitario La Paz, IDIPAZ, Madrid, Spain.

15 7: Université des Antilles et de la Guyane, Faculté de Médecine Hyacinthe Bastaraud, EA 4537 ,
16 Pointe-à-Pitre, France.

17 8: Centre Hospitalier Universitaire de Pointe-à-Pitre, Inserm CIC1424, Service de Maladies
18 Infectieuses et Tropicales, Dermatologie, Médecine Interne, Pointe-à-Pitre, France.

19 9: Department of Infectious Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia.

20 10: Ninewells Hospital and Medical School, Dundee, Scotland DD19SY UK.

21 **Corresponding author:**

22 Dr Guillaume Béraud,

23 Médecine Interne et Maladies Infectieuses, Centre Hospitalier de Poitiers. 2, rue de la Milétrie 86000
24 Poitiers.

25 +33 (0)6.82.75.27.26 / beraudguillaume@gmail.com

26

27 **Running title:** Controversies in endocarditis antibiotic treatment

28 **Key words:** Endocarditis, guidelines, anti-bacterial agents, gentamicin, Methicillin-Resistant

29 Staphylococcus aureus

30 **Abstract:**

31 International guidelines are available to help physicians prescribe appropriate antibiotic regimens to
32 patients with infective endocarditis (IE). However some topics of these guidelines are controversial.
33 We conducted an international survey to assess physicians' adherence to these guidelines, focusing on
34 these controversial items.

35 An invitation to participate to a 15-question online survey was sent in 2012-2013 to ESCMID
36 members, scientific societies and corresponding authors of publications on IE mentioned in Pubmed
37 from 1990 to 2012, inclusive.

38 Eight hundred and thirty-seven physicians participated in the survey and 625 (74.7%) completed it
39 over the first question. The results showed great heterogeneity of practices. Claiming to follow
40 guidelines was marginally associated with more guidelines-based strategies. Gentamicin use depended
41 on causative pathogens ($p < 0.001$) and physician's specialty ($p = 0.02$). Eighty-six percent of the
42 physicians favoured vancomycin alone or in combination with gentamicin or rifampicin as a first-line
43 treatment for left-sided native valve MRSA IE, 31% considered switching to oral therapy as a
44 therapeutic option and 33% used the ampicillin and ceftriaxone combination for enterococcal IE as a
45 first-line therapy. Physician's specialty significantly impacted the choice of a therapeutic strategy,
46 while practicing in a university hospital or the number of years of practice had virtually no impact.

47 Our survey, the largest on infective endocarditis treatment, underscores important heterogeneity in
48 practices for treatment of IE. Nonetheless, physicians who do not follow guidelines can have very
49 rational strategies based on literature. These results could inform the revision of future guidelines, and
50 identify unmet need for future studies.

51 **Introduction**

52 European guidelines on the diagnosis and treatment of infective endocarditis (IE) were updated in
53 October 2009 [1] and are in accordance with the US guidelines [2] for many situations. Some aspects
54 of antibiotic strategies remain controversial, not only because there are relatively few studies
55 contributing to informing evidence or expert based guidance but also because IE is a heterogeneous
56 syndrome, managed by different specialties with different experiences, and consequently with
57 different opinions as regards the optimal strategy. Moreover, some specific topics have yet to be
58 addressed in the existing guidelines, and it is not surprising that a recent study on gentamicin use in IE
59 involving French physicians underscored heterogeneous practices and degrees of guideline
60 adherence[3]. Furthermore, underreported conflicts of interest may also be a barrier to adherence [4].

61 We conducted an international survey on treatment of IE with the aims of assessing physicians'
62 adherence to guidelines and highlight controversial endocarditis-related topics that may need to be
63 addressed in future guidelines and studies.

64

65 **Material and Methods**

66 *Survey design*

67 A cross-sectional survey on therapeutic choices in infective endocarditis was developed in
68 collaboration with 4 infectious disease experts. The 15-question online survey was drawn up via
69 surveymonkey.com and made available via a weblink (<http://www.surveymonkey.com/s/N7Y2R95>)
70 (Table 1). A pilot survey was conducted with 10 physicians to test clarity. An invitation to participate
71 in the online survey was sent to ESCMID members and to scientific societies involved in management
72 of IE (Supporting information). Similar invitations were sent to all the corresponding authors (n=2126)
73 of publications on IE mentioned in Pubmed from 1990 to 2012. Invitations were also posted on forums
74 dedicated to infectious diseases (Supporting information). The survey was made available over a 3-
75 month period (November 2012 – January 2013), with reminders sent by e-mail twice, 1 and 2 months
76 after the first invitation. Participation was entirely voluntary and anonymous, without any
77 compensation. No ethical approval was needed in accordance with French regulation.

78 Prior to analysis, physicians' strategies were classified as guideline-based, literature-based or «other»
79 (Table 2). Any strategy based on European, US or British guidelines was considered as guideline-
80 based and any strategy not guideline based, but matching some strategy published in a peer-reviewed
81 article was considered as literature-based. Concerning the use of gentamicin, strategies were defined
82 according to the pathogen of interest. In summary, a once-daily high dose (>3mg/kg/d) of gentamicin
83 was systematically considered as a literature-based strategy [5], while a daily divided high dose was
84 categorized as «other». Once-daily dosing was considered to be a literature-based strategy [5] except
85 when associated with a standard dose (3mg/kg/d) in the treatment of streptococcal endocarditis [1].
86 Moreover, a physician applying a guideline-based strategy monitored gentamicin peaks at the
87 beginning of treatment and trough at beginning and regularly during treatment and used vancomycin
88 based treatment for MRSA IE first-line treatment [1,2,6]. Literature-based strategy involved switching
89 to oral antibiotic therapy for uncomplicated left-sided IE[7] or using amoxicillin + ceftriaxone
90 combination for *Enterococcus faecalis* IE[8].

91 *Statistical analysis*

92 Analyses were performed using the statistical programming language R [9]. All variables being
93 categorical, they were compared with a Pearson's χ^2 test when applicable, otherwise a Fisher exact
94 test was used. Unsupervised learning was used to identify patterns among countries with the R
95 package tree 1.0.

96

97 **Results**

98 Descriptive results are presented in Table 1. Eight hundred and thirty-seven physicians participated in
99 the survey, but only 625 (74.7%) completed it over the first question and 607 (72.5%) answered all the
100 questions. Hence, results are presented for a total of 625 participants, most of whom were European
101 (n=453, 72.5%). Among them, 394 (63.0%) practiced in a university hospital, 357 (57.1%) were
102 infectious disease specialists, 433 (69.3%) had practiced for more than 10 years and 455 (72.8%)
103 considered that they were following guidelines concerning the use of gentamicin in infective
104 endocarditis.

105 Specialty was the main factor influencing the choice of a therapeutic strategy (Table 3). Although
106 various combinations of preferred dose and regimen of gentamicin were reported (3, 4, ≥ 5 mg/kg/d,
107 once, twice, three times a day or not), specialty was strongly associated with the preferred regimen, as
108 was global strategy for the use of gentamicin independently of the pathogen ($p=0.02$) and among
109 pathogens (Table 3). In terms of the strategy (guideline, literature or other) associated with gentamicin
110 use, pathogens in themselves had an influence ($p<0.001$) (figure 1). Moreover, specialty influenced
111 use of the ampicillin and ceftriaxone combination for enterococcal IE ($p=0.03$), gentamicin peak
112 monitoring ($p<0.001$), the oral switch for left IE ($p=0.02$) and the first line treatment for MRSA
113 endocarditis (vancomycin-based and linezolid treatment ($p\leq 0.001$)). Vancomycin monotherapy was
114 favoured by infectious disease specialists, in combination with gentamicin and rifampicin by
115 intensivists and clinical microbiologists respectively.

116 Practicing in a university hospital was not associated with any particular strategy, except for increased
117 use of ampicillin with ceftriaxone (38.8% vs. 24.2%, $p<0.001$). Number of years of practice had no
118 influence either, with two noteworthy exceptions; 1. gentamicin use on staphylococcal IE, physicians
119 with more than 10 years of practice tended to use more a guideline-based strategy (58.7% vs. 47.4%)
120 and less "other" strategy (26.8% vs. 35.4%) ($p=0.03$); 2. for the first-line treatment for MRSA
121 endocarditis, vancomycin + gentamicin treatment was favoured by physicians with less than 10 years
122 of practice (57.8% (111/192) vs. 45.7% (198/433), $p=0.007$), while daptomycin-based treatments were

123 favoured by physicians with more than 10 years of practice (daptomycin + rifampin: 3.1% (6/192) vs
124 7.9% (34/433), $p=0.040$)(daptomycin + gentamicin: 3.6% (7/192) vs 9.2% (40/433), $p=0.022$).

125 Eighty-six percent of the physicians used vancomycin alone or in combination with gentamicin or
126 rifampicin as a first-line treatment for left-sided native valve MRSA IE. Thirty-one percent of the
127 physicians considered sometimes switching to oral therapy as a therapeutic option, but they did so
128 more frequently for streptococcal IE rather than for staphylococcal or enterococcal IE. Thirty-three
129 percent of the physicians sometimes used the ampicillin + ceftriaxone combination for enterococcal IE
130 (Table 1). Claiming to follow guidelines was marginally associated with more guidelines based
131 strategies (Supporting Information). Classification techniques were unable to identify patterns of
132 practice among different countries.

133

134 **Discussion**

135 We found wide variations in practices for treatment of IE, even though all the topics were considered
136 by the guidelines. Studies have shown that adherence to guidelines is low. A recent one underscored
137 the fact that 66% of the initial gentamicin dosing did not follow the hospital guidelines[10].

138 Consequently, publication of the guidelines does not always suffice and careful implementation is
139 likely to remain highly necessary. Barriers to physician's adherence to guidelines are multiple and
140 have been widely described in literature [11]and how they may be implemented more effectively is
141 subject to much attention [12].

142 In addition to the many reasons for poor guideline compliance, in relation to IE, discrepancies
143 between published guidelines and physician practices could simply reflect inherent discrepancies
144 between the US[2], European[1] and British[6] guidelines (table 2), which were published over a 7
145 years' period.

146 Nonetheless, we showed that physicians who do not follow guidelines can have an alternative and
147 reasonable scientific approach based on their awareness and interpretation of the literature. Whether
148 this is as "rational" as the guideline based approach is a moot point as the recommendations of good
149 guidelines should stem from a scientifically robust methodological approach to evidence synthesis and
150 evaluation. Therefore, they should by definition reflect the "best informed" scientific view on the
151 subject at that time. It appears from our data that non-adherence to guidelines often results from
152 respondents choosing to use information from other published data to inform their treatment decisions.
153 This clearly introduces a high degree of selectivity and subjectivity to the decision process. The high
154 use of other sources as a means of informing practice is clearly a source of concern. Even more
155 disturbing is the fact that "other" strategies - by definition neither guidelines-based nor literature-based
156 - were hardly exceptional, if not predominant regarding gentamicin use (31.2%, 37.1%, 42.9% for
157 staphylococcal, streptococcal and enterococcal IE, resp.).

158 Once-daily dosing of aminoglycosides is currently accepted as safe, effective and optimal. However,
159 given the absence of clinical trial data, US, European and British guidelines continue to recommend a

160 historical 2 or 3 equally divided low dose for gentamicin in *Staphylococci* (when using gentamicin)
161 and *Enterococci* IE (table 2), thereby respecting long-standing habit. The situation with regard to
162 *Streptococci* IE used to be similar, but studies[13][14] has reported once-daily regimen as safe and
163 effective, thus now widely recommended. Nevertheless, a single dose of 5mg/kg of gentamicin
164 associated with daptomycin or vancomycin in an in vitro model of staphylococcal IE yielded earlier
165 bactericidal activity than three 1mg/kg doses over 24h in vitro[15]. Similar efficacy was likewise
166 observed with gentamicin given once-daily or three times daily, associated with ampicillin for an
167 enterococcal IE in rabbits[16]. Most importantly, gentamicin was administered safely and efficiently at
168 7mg/kg/d once-daily to 2184 patients presenting various situations, including endocarditis[5].
169 Consequently, even in cases of infective endocarditis the literature provides support for a once-daily
170 regimen of gentamicin. Moreover, in accordance with guidelines and literature, some physicians
171 simply do not use gentamicin in staphylococcal IE. Indeed, the only two studies evaluating gentamicin
172 in staphylococcal IE demonstrated no clear benefit, but rather a higher rate of renal failure[17][18].
173 In accordance with a recent French study[3], proportions of guidelines, literature or «other» strategies
174 on gentamicin use in IE depended on both the pathogens and the specialty of the physician. But the
175 importance of the specialty went beyond gentamicin use, and was also an influencing factor on the
176 preferred strategy for enterococcal IE, MRSA IE, oral switch or gentamicin monitoring. Of note,
177 intensivists were the least prone to «other» strategies, and the most prone to literature-based strategies.
178 As for the differences between specialists, they can be largely explained by their differing experience
179 with IE. Intensivists are likely to be more concerned with acute and severe endocarditis, e.g
180 staphylococcal IE, than with subacute IE, e.g. enterococcal IE, and they consequently employ fewer
181 «other» strategies with staphylococcal IE than with enterococcal IE. And in addition to the influence
182 exerted by specialties, pathogens have an impact on the globally preferred strategy. As a matter of fact,
183 enterococcal IE is not common, and streptococcal IE can have very heterogeneous presentations, acute
184 as well as subacute, severe as well as non-severe, while staphylococcal IE usually presents little
185 heterogeneity, being frequently acute and severe, a factor that may explain the low proportion of
186 “other” strategies for staphylococcal IE. Conversely, the multiple and heterogeneous presentations of

187 streptococcal IE and, particularly, enterococcal IE tend to favour multiple and heterogeneous
188 strategies.

189 Vancomycin-based treatment is the long-time gold standard for MRSA IE. However, its slow
190 bactericidal activity, and a more recent trend for increased MIC (minimum inhibitory concentration),
191 prompted the need for alternative therapeutic options. Alternative treatments for MRSA IE are
192 daptomycin[19] and to a lesser extent linezolid[20], but no studies have shown them to be superior to
193 vancomycin. The small number of published studies and the low level of evidence for the efficiency of
194 alternative treatments may help to explain why participants were more reluctant to use new approaches
195 and preferred more conventional treatment of MRSA.

196 Guidelines do not recommend an oral switch in IE treatment, except for right-sided IE in injection
197 drug users, as suggested in two old studies[21,22]. No studies supporting an oral switch for left-sided
198 endocarditis was published before guidelines, with the exception of case reports or case series[23,24].
199 More recently, an observational single-center study reported an oral switch for 19 cases of IE, mainly
200 left-sided (n=12) and primarily due to *Staphylococci* (n=12)[7]. Two randomized clinical trial
201 evaluating the oral switch for staphylococcal, streptococcal and enterococcal left-sided IE (RODEO
202 study, France) and all causes left-sided IE (POET study, Denmark[25]) are underway or about to start.
203 Infectious disease specialists have been the only ones to publish articles dealing with oral switch
204 hitherto, but they were actually the least prone to switch to oral therapy for left-sided endocarditis with
205 good response to parenteral therapy. Physicians who might be inclined to switch to oral therapy are
206 more likely to do so for streptococcal IE rather than staphylococcal IE, which could reflect their fear
207 of the severity of staphylococcal IE.

208 With population aging, enterococcal IE becomes more frequent, and maintaining a long course of
209 gentamicin associated with ampicillin may be difficult, particularly in terms of nephrotoxicity.
210 Moreover, the increasing prevalence of high-level aminoglycoside resistance highlights the need for
211 alternative treatment. More recently, for *E. faecalis* IE the ampicillin and ceftriaxone combination
212 showed efficiency similar to that of the ampicillin and gentamicin association but with less renal

213 failure[26] . The recent nature of the supporting evidence and the relative infrequent nature of these
214 infections, may explain why this regimen has been preferred by ID specialists and cardiologists from
215 university hospitals.

216 Even though participants came from numerous countries, we found no clear patterns of prescriptions
217 according to the country. While such patterns may simply not exist, their absence may possibly arise
218 from a selection bias in our study. Indeed, our study presents some limitations. European participants
219 clearly predominate, while the speciality of clinical microbiology does not exist in every country [27],
220 e.g. in France. Moreover, participation in the survey was purely voluntary and our invitation to
221 participate in the survey was primarily addressed to physicians with a pronounced interest in infective
222 endocarditis. The participating physicians, who are likely to be those with the most expertise on IE,
223 may consequently not be fully representative. In addition, as we were unable to estimate a response
224 rate, it is difficult to determine to what degree our study is representative. That said, it is the largest
225 survey on infective endocarditis treatment ever published, and the proportion of physicians using
226 «other» strategies might be even higher if a wider or more representative sampling of physicians were
227 to be used.

228 This is a unique, large, survey of real world clinician practice in relation to endocarditis antibiotic
229 treatment. We have identified that most of the physicians do not follow published guidelines on
230 infective endocarditis. This could result from the differences in practice experience as well as from the
231 discrepancies between various guidelines. Nonetheless, participants who do not follow guidelines can
232 adopt reasonable approaches based on use and personal interpretation of existing literature. We also
233 identified that their information strategies (whether guidelines or literature based) and practices
234 varying widely by pathogens and clinical specialty. When guidelines are developed, disseminated and
235 implemented a range of important factors ought to be considered. These include the need to recognise
236 the target audience, their skills and practice, the importance of recommendations to be based on good
237 and up to date evidence, the needs for some consistency between existing or new guidance, the need to
238 identify areas of uncertainty and where there is a need for further research. We hope that some of our
239 findings will support and inform the revision of future guidelines.

240

241 **Acknowledgement:**

242 The authors thank Henri Saenz for his invaluable help for the implementation of the survey, and

243 Jeffrey Arsham, a medical translator, for reading and reviewing the original English-language text.

244 Some of the results have been presented as an e-poster with a short oral presentation at 24th ECCMID

245 in Barcelona in 2014.

246 **Funding:** This study was conducted as part of our routine work.247 **Transparency declarations:** None to declare.248 **References**

- 249 [1] Habib G, Hoen B, Tornos P, Thuny F, Prendergast B, Vilacosta I, et al. Guidelines on the
250 prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task
251 Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European
252 Society of Cardiology (ESC). *Eur Heart J* 2009;30:2369–413. doi:ehp285 [pii]
253 10.1093/eurheartj/ehp285.
- 254 [2] Baddour LM, Wilson WR, Bayer AS, Fowler VG, Bolger AF, Levison ME, et al. Infective
255 endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement
256 for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and
257 Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical
258 Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association:
259 endorsed by the Infectious Diseases Society of America. *Circulation* 2005;111:e394–434.
260 doi:111/23/e394 [pii] 10.1161/CIRCULATIONAHA.105.165564.
- 261 [3] Béraud G, Le Moal G, Elsendoorn A, Tattevin P, Godet C, Alfandari S, et al. A survey on the use
262 of gentamicin in infective endocarditis. *Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin*
263 *Microbiol* 2011. doi:10.1007/s10096-011-1458-9.
- 264 [4] Raoult D, Hope W, Kahlmeter G. Guidelines need controls. *Clin Microbiol Infect Off Publ Eur Soc*
265 *Clin Microbiol Infect Dis* 2015. doi:10.1016/j.cmi.2015.09.010.
- 266 [5] Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a
267 once-daily aminoglycoside program administered to 2,184 adult patients. *Antimicrob Agents*
268 *Chemother* 1995;39:650–5. doi:Clinical Trial.
- 269 [6] Gould FK, Denning DW, Elliott TSJ, Foweraker J, Perry JD, Prendergast BD, et al. Guidelines for
270 the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party
271 of the British Society for Antimicrobial Chemotherapy. *J Antimicrob Chemother* 2012;67:269–
272 89. doi:10.1093/jac/dkr450.
- 273 [7] Demonchy E, Dellamonica P, Roger PM, Bernard E, Cua E, Pulcini C. Audit of antibiotic therapy
274 used in 66 cases of endocarditis. *Médecine Mal Infect* 2011;41:602–7.
275 doi:10.1016/j.medmal.2011.08.003.
- 276 [8] Gavalda J, Len O, Miró JM, Muñoz P, Montejo M, Alarcón A, et al. Brief communication:
277 treatment of *Enterococcus faecalis* endocarditis with ampicillin plus ceftriaxone. *Ann Intern*
278 *Med* 2007;146:574–9.
- 279 [9] R Development Core Team. R: A language and environment for statistical computing. R
280 Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. 2012.

- 281 [10] Leong CL, Buising K, Richards M, Robertson M, Street A. Providing guidelines and education is
282 not enough: an audit of gentamicin use at The Royal Melbourne Hospital. *Intern Med J*
283 2006;36:37–42. doi:IMJ [pii] 10.1111/j.1445-5994.2006.01002.x.
- 284 [11] Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, et al. Why don't physicians
285 follow clinical practice guidelines? A framework for improvement. *JAMA* 1999;282:1458–65.
- 286 [12] Gagliardi AR, Brouwers MC, Palda VA, Lemieux-Charles L, Grimshaw JM. How can we improve
287 guideline use? A conceptual framework of implementability. *Implement Sci IS* 2011;6:26.
288 doi:10.1186/1748-5908-6-26.
- 289 [13] Francioli P, Ruch W, Stamboulian D. Treatment of streptococcal endocarditis with a single daily
290 dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter study. *Clin Infect Dis*
291 1995;21:1406–10.
- 292 [14] Sexton DJ, Tenenbaum MJ, Wilson WR, Steckelberg JM, Tice AD, Gilbert D, et al. Ceftriaxone
293 once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks
294 for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment
295 Consortium Group. *Clin Infect Dis* 1998;27:1470–4.
- 296 [15] Tsuji BT, Rybak MJ. Short-course gentamicin in combination with daptomycin or vancomycin
297 against *Staphylococcus aureus* in an in vitro pharmacodynamic model with simulated
298 endocardial vegetations. *Antimicrob Agents Chemother* 2005;49:2735–45. doi:49/7/2735 [pii]
299 10.1128/AAC.49.7.2735-2745.2005.
- 300 [16] Gavalda J, Cardona PJ, Almirante B, Capdevila JA, Laguarda M, Pou L, et al. Treatment of
301 experimental endocarditis due to *Enterococcus faecalis* using once-daily dosing regimen of
302 gentamicin plus simulated profiles of ampicillin in human serum. *Antimicrob Agents Chemother*
303 1996;40:173–8.
- 304 [17] Korzeniowski O, Sande MA. Combination antimicrobial therapy for *Staphylococcus aureus*
305 endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study.
306 *Ann Intern Med* 1982;97:496–503.
- 307 [18] Cosgrove SE, Vigliani GA, Fowler VG, Abrutyn E, Corey GR, Levine DP, et al. Initial low-dose
308 gentamicin for *Staphylococcus aureus* bacteremia and endocarditis is nephrotoxic. *Clin Infect*
309 *Dis Off Publ Infect Dis Soc Am* 2009;48:713–21. doi:10.1086/597031.
- 310 [19] Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al., *S. aureus*
311 Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia
312 and endocarditis caused by *Staphylococcus aureus*. *N Engl J Med* 2006;355:653–65.
313 doi:10.1056/NEJMoa053783.
- 314 [20] Lauridsen TK, Bruun LE, Rasmussen RV, Arpi M, Risum N, Moser C, et al. Linezolid as rescue
315 treatment for left-sided infective endocarditis: an observational, retrospective, multicenter
316 study. *Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol* 2012;31:2567–74.
317 doi:10.1007/s10096-012-1597-7.
- 318 [21] Heldman AW, Hartert TV, Ray SC, Daoud EG, Kowalski TE, Pompili VJ, et al. Oral antibiotic
319 treatment of right-sided staphylococcal endocarditis in injection drug users: prospective
320 randomized comparison with parenteral therapy. *Am J Med* 1996;101:68–76.
- 321 [22] Dworkin RJ, Lee BL, Sande MA, Chambers HF. Treatment of right-sided *Staphylococcus aureus*
322 endocarditis in intravenous drug users with ciprofloxacin and rifampicin. *Lancet* 1989;2:1071–3.
- 323 [23] Levine DP, Preston Holley H, Eiseman I, Willcox P, Tack K. Clinafloxacin for the Treatment of
324 Bacterial Endocarditis. *Clin Infect Dis* 2004;38:620–31. doi:10.1086/381670.
- 325 [24] Parker RH, Fossieck BE. Intravenous followed by oral antimicrobial therapy for staphylococcal
326 endocarditis. *Ann Intern Med* 1980;93:832–4.
- 327 [25] Iversen K, Høst N, Bruun NE, Elming H, Pump B, Christensen JJ, et al. Partial oral treatment of
328 endocarditis. *Am Heart J* 2013;165:116–22. doi:10.1016/j.ahj.2012.11.006.
- 329 [26] Fernández-Hidalgo N, Almirante B, Gavalda J, Gurgui M, Peña C, de Alarcón A, et al. Ampicillin
330 plus ceftriaxone is as effective as ampicillin plus gentamicin for treating *enterococcus faecalis*
331 infective endocarditis. *Clin Infect Dis Off Publ Infect Dis Soc Am* 2013;56:1261–8.
332 doi:10.1093/cid/cit052.

- 333 [27] Read RC, Cornaglia G, Kahlmeter G, European Society of Clinical Microbiology and Infectious
334 Diseases Professional Affairs Workshop group. Professional challenges and opportunities in
335 clinical microbiology and infectious diseases in Europe. *Lancet Infect Dis* 2011;11:408–15.
336 doi:10.1016/S1473-3099(10)70294-2.
337

ACCEPTED MANUSCRIPT

Table 1 : Descriptive results

Questions	Answers	n (N=625, except otherwise specified) (%)
Where do you currently reside? (N=837)	Africa	8 (1.0)
	Asia or Australasia	94 (11.2)
	Europa	591 (70.6)
	Middle East	51 (6.1)
	North or South America	93 (11.1)
	France	99 (21.9)
	Spain	69 (15.2)
	Italy	42 (9.3)
	UK	34 (7.5)
	In which country do you currently reside? (N=453) (most frequent answers)	Germany
Greece		19 (4.2)
Netherlands		19 (4.2)
Sweden		16 (3.5)
Belgium		15 (3.3)
Romania		14 (3.1)
Other European countries (24)		105 (23.2)
University hospital		394 (63.0)
Non university hospital		201 (32.2)
Others		30 (4.8)
Where do you practice?	Infectious diseases	357 (57.1)
	Cardiology	39 (6.2)
	Intensive care	32 (5.1)
	Clinical microbiology	127 (20.3)
	Others	70 (11.2)
What is your specialty?	More than 10 years	433 (69.3)
	Less than 10 years	192 (30.7)
	Guidelines (US 2005 and/or European 2009 and/or BSAC 2012)	455 (72.8)
Concerning the use of gentamicin in infective endocarditis, is your practice based on:	Personal expertise	105 (10.4)
	Department/facility protocol	65 (16.8)
	3 mg/kg/d	394 (63.1)
Which dose of gentamicin do you use in a patient with endocarditis and normal renal function?	4 mg/kg/d	77 (12.3)
	5 mg/kg/d or more	154 (24.6)
	I usually don't use aminosides in staphylococcal IE	210 (33.6)
Which regimen of gentamicin do you use in a patient with endocarditis due to <i>Staphylococcus</i>, and normal renal function?	Once a day	204 (32.6)
	Twice a day	73 (11.7)
	Three times a day	138 (22.1)
	I usually don't use aminosides in Streptococcal EI	146 (23.3)
Which regimen of gentamicin do you use in a patient with endocarditis due to <i>Streptococcus</i>, and normal renal function?	Once a day	248 (39.7)
	Twice a day	75 (12.0)
	Three times a day	156 (25.0)
	I usually don't use aminosides in Enterococcal EI	62 (9.9)
Which regimen of gentamicin do you use in a patient with endocarditis due to <i>Enterococcus</i>, and normal renal function?	Once a day	189 (30.2)
	Twice a day	126 (20.2)
	Three times a day	248 (39.7)
	Never	283 (45.3)
When do you monitor gentamicin peak		

concentrations in plasma?	At the beginning of treatment only	112 (17.9)
	Regularly during treatment	230 (36.8)
	Never	150 (24.0)
When do you monitor gentamicin trough concentrations in plasma?	At the beginning of treatment only	42 (6.7)
	Regularly during treatment	433 (69.3)
Do you sometimes switch to oral therapy for left-sided uncomplicated endocarditis, when the clinical and microbiological response to parenteral therapy has been good: (N=621)	Yes	195 (31.4)
	No	427 (68.6)
For which clinical situations regarding left-sided endocarditis, do you switch to oral therapy (considering the pathogen is susceptible to antibiotics with an excellent bioavailability): (N=188) (<i>several answers possible</i>)	Streptococcal endocarditis	115 (61.2)
	Enterococcal endocarditis	41 (21.8)
	Staphylococcal endocarditis	66 (35.1)
	Native valve endocarditis	116 (61.7)
	Prosthetic valve endocarditis	24 (12.8)
	Uncomplicated endocarditis	153 (81.4)
	Other	150 (24.7)
What is your first line treatment for MRSA left sided endocarditis on native valve (considering you don't have any MIC yet) (N=607) (<i>several answers possible</i>)	Vancomycin + gentamicin	309 (50.9)
	Vancomycin + rifampicin	85 (14.0)
	Daptomicin + rifampicin	40 (6.6)
	Daptomicin + gentamicin	47 (7.7)
	Linezolid	17 (2.8)
	Other	36 (5.9)
	Other	36 (5.9)
Do you sometimes use the association IV amoxicillin + ceftriaxone as a first line treatment for native valve <i>Enterococcus faecalis</i> left sided endocarditis? (N=607)	Yes	203 (33.4)
	No	404 (66.6)


Table 2: Classification of strategies in guidelines based, literature based or “other” strategies.

Controversial point	Guideline based (BSAC 2012)	Guideline based (AHA 2005)	Guideline based (Habib et al. 2009)	Literature based	Other
Staphylococcal IE	No aminoglycoside	daily divided standard dose (3/d) or no aminoglycoside	daily divided standard dose or no aminoglycoside ^{16,17}	once-daily standard or high dose ⁵	daily divided high dose
Streptococcal IE	Twice a day with a low dose (1mg/kg/12h) or no aminoglycoside	once-daily standard dose (or no aminoglycoside if low MIC and 4-week treatment) or 3 times a day alternatively	once-daily standard dose (or no aminoglycoside if low MIC and 4-week treatment)	once-daily high dose ⁵	daily divided standard or high dose
Enterococcal IE	Twice a day with a low dose(1mg/kg/12h)	daily divided standard dose (3/d)	daily divided standard dose	once-daily standard or high dose ⁵	daily divided high dose (or no aminoglycoside)
Gentamicin peak monitoring	Regularly	Yes, but without precision on the schedule	At the beginning of treatment or Regularly during treatment		Never
Gentamicin trough monitoring	Regularly	Yes, but without precision on the schedule	Regularly during treatment		At the beginning of treatment / Never
Oral switch for left IE	No	No	No	Yes ⁶	
MRSA left sided endocarditis on native valve	Vancomycin + rifampicin	Vancomycin	Vancomycin (+ gentamicin)(optional)	All other treatments cited in the questionnaire ^{18,19}	
Amoxicillin+ ceftriaxone for E. faecalis IE	No	No	No	Yes ¹⁵	

Table 3: Influence of the specialty

		Infectious diseases (n=357)	Clinical microbiology (n=127)	Intensive care (n=32)	Cardiology (n=39)	Others (n=70)	p
Gentamicin dose	3 mg/kg/d	235 (65.8)	81 (63.8)	14 (43.7)	28 (71.8)	36 (51.4)	0.020
	> 3 mg/kg/d	122 (34.2)	46 (36.2)	18 (56.3)	11 (28.2)	34 (48.6)	
Gentamicin regimen in <i>Staphylococcus</i> endocarditis	No aminosides	137 (38.4)	42 (33.1)	5 (15.6)	5 (12.8)	21 (30.0)	<0.001
	Once a day	127 (35.6)	29 (22.8)	17 (53.1)	11 (28.2)	20 (28.6)	
	> Once a day	93 (26.0)	56 (44.1)	10 (31.3)	23 (59.0)	29 (41.4)	
Strategy for <i>Staphylococcus</i> endocarditis	Guideline-based	197 (55.2)	77 (60.6)	12 (37.5)	22 (56.4)	37 (52.9)	0.015
	Literature based	58 (16.2)	14 (11.0)	12 (37.5)	2 (5.1)	10 (14.3)	
	Other	102 (28.6)	36 (28.4)	8 (25.0)	15 (38.5)	23 (32.9)	
Gentamicin regimen in <i>Streptococcus</i> endocarditis	No aminosides	95 (26.6)	21 (16.5)	3 (9.4)	8 (20.5)	19 (27.1)	<0.001
	Once a day	150 (42.0)	40 (31.5)	19 (59.4)	19 (48.7)	20 (28.6)	
	> Once a day	112 (31.4)	66 (52.0)	10 (31.2)	12 (30.8)	31 (44.3)	
Strategy for <i>Streptococcus</i> endocarditis	Guideline-based	183 (51.2)	41 (32.3)	9 (28.1)	23 (59.0)	29 (41.4)	<0.001
	Literature based	62 (17.4)	20 (15.7)	13 (40.6)	4 (10.2)	10 (14.3)	
	Other	112 (31.4)	66 (52.0)	10 (31.3)	12 (30.8)	31 (44.3)	
Gentamicin regimen in <i>Enterococcus</i> endocarditis	No aminosides	26 (7.3)	18 (14.2)	2 (6.3)	3 (7.7)	13 (18.6)	0.032
	Once a day	114 (31.9)	29 (22.8)	13 (40.6)	15 (38.5)	18 (25.7)	
	> Once a day	217 (60.8)	80 (63.0)	17 (53.1)	21 (53.8)	39 (55.7)	
Strategy for <i>Enterococcus</i> endocarditis	Guideline-based	160 (44.8)	51 (40.2)	10 (31.3)	15 (38.4)	21 (30.0)	0.042
	Literature based	54 (15.1)	12 (9.4)	9 (28.1)	4 (10.3)	11 (15.7)	
	Other	143 (40.1)	64 (50.4)	13 (40.6)	20 (51.3)	38 (54.3)	
Gentamicin peak monitoring	Never	61 (17.1)	24 (18.9)	14 (43.7)	1 (2.6)	12 (17.1)	<0.001
	At the beginning of treatment only	187 (52.4)	49 (38.6)	10 (31.3)	10 (25.6)	27 (38.6)	
	Regularly during treatment	109 (30.5)	54 (42.5)	8 (25.0)	28 (71.8)	31 (44.3)	
Gentamicin trough monitoring	Never	26 (7.3)	5 (3.9)	5 (15.6)	0 (0.0)	6 (8.6)	0.078
	At the beginning of treatment only	83 (23.2)	31 (24.4)	4 (12.5)	9 (23.1)	23 (32.9)	
	Regularly during treatment	248 (69.5)	91 (71.7)	23 (71.9)	30 (76.9)	41 (58.6)	
Oral switch for left IE	Yes	93 (26.1)	50 (39.7)	10 (32.3)	14 (35.9)	28 (40.0)	0.022
Clinical situations with switch to oral therapy	Streptococcal endocarditis	54 (15.1)	29 (22.8)	6 (18.7)	11 (28.2)	15 (21.4)	0.129
	Enterococcal endocarditis	16 (4.5)	15 (11.8)	3 (9.4)	1 (2.6)	6 (8.6)	0.035
	Staphylococcal endocarditis	40 (11.2)	15 (11.8)	4 (12.5)	1 (2.6)	6 (8.6)	0.468
	Native valve endocarditis	60 (16.8)	24 (18.9)	7 (21.9)	12 (30.8)	13 (18.6)	0.307
	Prosthetic valve endocarditis	11 (3.1)	7 (5.5)	1 (3.1)	1 (2.6)	4 (5.7)	0.599
	Uncomplicated endocarditis	70 (19.6)	42 (33.1)	7 (21.9)	14 (35.9)	20 (28.6)	0.011
First line treatment for MRSA	Vancomycin	112 (31.4)	23 (18.1)	3 (9.4)	4 (10.3)	8 (11.4)	<0.001
	Vancomycin +	166 (46.5)	53 (41.7)	22 (68.8)	29 (74.4)	39 (55.7)	<0.001

endocarditis	gentamicin						
	Vancomycin + rifampicin	36 (10.1)	32 (25.2)	2 (6.3)	5 (12.8)	10 (14.3)	0.001
	Daptomicin + rifampicin	28 (7.8)	6 (4.7)	3 (9.4)	1 (2.6)	2 (2.9)	0.352
	Daptomicin + gentamicin	31 (8.7)	6 (4.7)	3 (9.4)	0 (0.0)	7 (10.0)	0.143
	Linezolid	3 (0.8)	6 (4.7)	0 (0.0)	2 (5.1)	6 (8.6)	0.001
Amox + Ceftriax. in <i>E.faecalis</i> endoc.	Yes	127 (35.9)	27 (22.7)	7 (23.3)	15 (38.5)	27 (41.5)	0.028



ACCEPTED MANUSCRIPT